MK-4541 (100 mg/kg; p.o.; 5 times per week for 5 weeks) inhibits prostate tumor growth in athymic nude mice bearing R-3327-G cells[1].
MK-4541 (100 mg/kg, 200 mg/kg; p.o.; 5 times per week for 5 weeks) exhibits anti-androgen effects on the seminal vesicles, reduces plasma testosterone concentrations in intact males, and inhibits Ki67 expression[1].
MK-4541 (15 mg/kg, 50 mg/kg; p.o.; 5 times per week for 8 weeks) causes the loss of musculoskeletal mass and function in adult castrated mice[1].
| Animal Model: | R3327-G prostate tumors in xenograft mouse model[1] |
| Dosage: | 25 mg/kg, 50 mg/kg, 100 mg/kg, 200 mg/kg |
| Administration: | Oral gavage; once daily, 5 times per week for 5 weeks |
| Result: | Significantly inhibited tumor growth at 100 mg/kg, as well as reducing plasma testosterone concentration and Ki67 expression. |
![Carbamic acid, N-[(4aR,4bS,6aS,7S,9aS,9bS,11aR)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1,4a,6a-trimethyl-2-oxo-1H-indeno[5,4-f]quinolin-7-yl]-, 2,2,2-trifluoroethyl ester Structure](https://www.chemicalbook.com/CAS/20210111/GIF/796885-38-6.gif)
